These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 33967177)
1. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177 [TBL] [Abstract][Full Text] [Related]
5. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma]. Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387 [TBL] [Abstract][Full Text] [Related]
6. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging. You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520 [TBL] [Abstract][Full Text] [Related]
8. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma. Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915 [TBL] [Abstract][Full Text] [Related]
9. Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET. Uchinomura S; Mitamura K; Norikane T; Yamamoto Y; Oishi A; Hatakeyama T; Miyake K; Nishiyama Y Nucl Med Commun; 2022 Mar; 43(3):270-274. PubMed ID: 34864812 [TBL] [Abstract][Full Text] [Related]
10. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136 [TBL] [Abstract][Full Text] [Related]
11. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma? Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204 [TBL] [Abstract][Full Text] [Related]
12. Kong Z; Jiang C; Zhu R; Feng S; Wang Y; Li J; Chen W; Liu P; Zhao D; Ma W; Wang Y; Cheng X Neuroimage Clin; 2019; 23():101912. PubMed ID: 31491820 [TBL] [Abstract][Full Text] [Related]
13. Atypical primary central nervous system lymphoma and glioblastoma: multiparametric differentiation based on non-enhancing volume, apparent diffusion coefficient, and arterial spin labeling. Yu X; Hong W; Ye M; Lai M; Shi C; Li L; Ye K; Xu J; Ai R; Shan C; Cai L; Luo L Eur Radiol; 2023 Aug; 33(8):5357-5367. PubMed ID: 37171492 [TBL] [Abstract][Full Text] [Related]
14. Differentiation of high-grade glioma and primary central nervous system lymphoma: Multiparametric imaging of the enhancing tumor and peritumoral regions based on hybrid Zhang S; Wang J; Wang K; Li X; Zhao X; Chen Q; Zhang W; Ai L Eur J Radiol; 2022 May; 150():110235. PubMed ID: 35290912 [TBL] [Abstract][Full Text] [Related]
15. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient. Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023 [TBL] [Abstract][Full Text] [Related]
16. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis. Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843 [TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma. Kawai N; Miyake K; Yamamoto Y; Nishiyama Y; Tamiya T Biomed Res Int; 2013; 2013():247152. PubMed ID: 23844359 [TBL] [Abstract][Full Text] [Related]
18. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI. Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047 [TBL] [Abstract][Full Text] [Related]
19. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging. Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220 [TBL] [Abstract][Full Text] [Related]
20. Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation. Yamaguchi S; Hirata K; Kaneko S; Kobayashi H; Shiga T; Kobayashi K; Onimaru R; Shirato H; Tamaki N; Terasaka S; Houkin K Acta Neurochir (Wien); 2015 Feb; 157(2):187-94. PubMed ID: 25488176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]